Clinical Trial

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to study ISM8207 in participants with advanced solid tumors and relapsed/refractory B-cell lymphoma. The primary objective is to evaluate the safety and tolerability of ISM8207 orally administered in participants with advanced solid tumors and relapsed/refractory B-cell lymphoma
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-31; most recent amendment 2026-07-23.
Trial Details
NCT Number NCT06445517
Lead Sponsor InSilico Medicine Hong Kong Limited
Conditions Advanced Solid Tumors, Relapsed/Refractory B-cell Lymphoma
Enrollment 60 participants
Start Date 2024-04-25
Primary Completion 2026-11-30 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-07-24